eFFECTOR Therapeutics, Inc.
EFTRDelisted Jul 19, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001828522
eFFECTOR Therapeutics, Inc. was delisted on Jul 19, 2024; its insiders filed their last Form 4 on Jun 13, 2024; 18 institutions reported holding it in 13F filings for Q2 2024, worth $251.1K in total; no superinvestor held it.
Holders of 5% or more of EFTR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of eFFECTOR Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of eFFECTOR Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
27 Schedule 13D and 13G filings on eFFECTOR Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 13, 20244:05 PM ET | Carlyle Group Inc. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Sectoral Asset Management Inc | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Pfizer Inc | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2024 | Sr One Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 5, 2024 | Altitude Life Science Ventures Fund II, L.P. | 13G/AOld format | – | – | – | SEC |
| Nov 22, 2023 | Column Group II, LP | 13D/AOld format | – | – | – | SEC |
| Sep 15, 2023 | Column Group II, LP | 13D/AOld format | – | – | – | SEC |
| Aug 18, 20234:16 PM ET | Carlyle Group Inc. | 13D/AOld format | – | – | – | SEC |
| Mar 7, 2023 | Altitude Life Science Ventures Fund II, L.P. | 13GOld format | – | New | – | SEC |
| Feb 14, 2023 | Empyrean Capital Partners, LP | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2023 | Sectoral Asset Management Inc | 13G/AOld format | – | – | – | SEC |
| Aug 19, 2022 | US Venture Partners X LP | 13D/AOld format | – | – | – | SEC |
| Aug 19, 2022 | US Venture Partners X LP | 13D/AOld format | – | – | – | SEC |
| Aug 11, 20224:55 PM ET | Carlyle Group Inc. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Sr One Capital Management, LLC | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Beryl Capital Management LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Pfizer Inc | 13GOld format | – | New | – | SEC |
| Feb 11, 2022 | Sectoral Asset Management Inc | 13GOld format | – | New | – | SEC |
| Jan 31, 2022 | Linden Capital L.P. | 13G/AOld format | – | – | – | SEC |
| Sep 13, 2021 | US Venture Partners X LP | 13DOld format | – | New | – | SEC |
| Sep 7, 2021 | Column Group II, LP | 13DOld format | – | New | – | SEC |
| Sep 3, 2021 | Abingworth LLP | 13DOld format | – | New | – | SEC |
| Aug 25, 2021 | Feis Lawrence Michael | 13G/AOld format | – | – | – | SEC |
| Aug 20, 2021 | Beryl Capital Management LLC | 13GOld format | – | New | – | SEC |
| Aug 17, 2021 | Feis Lawrence Michael | 13GOld format | – | New | – | SEC |
| Feb 8, 2021 | Linden Capital L.P. | 13GOld format | – | New | – | SEC |
| Jan 21, 2021 | Empyrean Capital Partners, LP | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell eFFECTOR Therapeutics, Inc. shares.
No Form 144 notices for eFFECTOR Therapeutics, Inc. are on file.